Semaglutide pill to outsell injection globally by 2027 Q2
Resolves: Global sales of semaglutide oral tablets exceed those of semaglutide injections for the first time in any quarter by Q2 2027.
user-generated· product
Semaglutide pill to outsell injection globally by 2027 Q2
Market overview
The convenience of the oral semaglutide pill—despite stricter administration requirements—will drive higher adoption than the weekly injection. Industry forecasts indicate oral formulations will surpass injectable sales by Q2 2027.
product prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
Global sales of semaglutide oral tablets exceed those of semaglutide injections for the first time in any quarter by Q2 2027.
Source: user-generated
More product markets
- Will Ocado partnership meet 35% productivity target? — 70% Yes
- Will DCI announce new EV contract worth >$50M? — 55% Yes
- Will the company announce a renewable energy contract by 2026-12-31? — 65% Yes
- Will enGene Therapeutics report positive interim data for DETAIL trial by Q1 2027? — 35% Yes
- Will Phase 2 enrollment reach 50/60 patients by 2026-12-31? — 90% Yes
- Will ServiceTitan announce a major AI partnership or acquisition by end of 2026? — 30% Yes
- Will fintech firms offering real-time fund verification see increased demand? — 75% Yes
- Will private label exceed 33% penetration by EOY? — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…